BARCELONA, Spain and DÜSSELDORF, Germany, Sept. 25, 2026 -- Neuraxpharm Group and Minoryx Therapeutics today announce that the European Commission (EC) has granted marketing authorisation under exceptional circumstances for NEZGLYAL®...


Relentlessly innovative, NuVasive develops and markets minimally disruptive surgical products and procedures for the spine. From its inception, it has focused on creating products, such as its nerve avoidance monitoring system, that contribute to faster, less invasive surgical procedures, speedier recovery times for patients, and shorter hospital stays.
NuVasive went public in 2004.